US FDA approves Pfizer's RSV vaccine

The approval comes less than a month after the FDA approved a similar shot by rival GSK Plc.

The USFDA approved Pfizer Inc’s respiratory syncytial virus vaccine for older adults, making it the second shot against the common respiratory disease that can be fatal for seniors. | Photo Credit: Reuters

The U.S. Food and Drug Administration (FDA) on Wednesday approved Pfizer Inc's respiratory syncytial virus (RSV) vaccine for older adults, making it the second shot against the common respiratory disease that can be fatal for seniors.

The approval comes less than a month after the FDA approved a similar shot by rival GSK Plc. Pfizer's vaccine was approved for people aged 60 and older, the company said, the same age group as GSK's shot.